Based on the experimental research carried out on rats, the ability of compound L17 to considerably reduce the intensity of the systemic inflammation  at an experimental myocardial infarction has been detected, which reduces the primary lesion, accelerates regeneration processes, and prevents  recurrence of  the  disease.

The established immune corrective effect on the severity of manifestations of the systemic inflammation presents the distinctive feature and originality of the method, which makes it possible to  recommend the use of L17 compound in the cases of extremely serious diseases having an inflammatory  process in pathogenesis.

Effect of compound L-17 on biochemical parameters of blood in the dynamics

of experimental myocardial infarction